Oura IPO Oversubscribed 4x, Seeks $2.2B

Oura, a health and fitness ring maker, is offering 50 million shares at $40-$44, aiming to raise up to $2.2B. The IPO is oversubscribed 4x, with pricing expected Sept. 29. The company's market cap could reach $14.1B. Goldman Sachs, Morgan Stanley, and others are leading the deal. Oura plans to list on the Nasdaq.

Original reporting
Published Sep 26, 2026, 11:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 7:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oura IPO Oversubscribed 4x, Seeks $2.2B — source image
Decision brief

The 30-second read

High
01

Why it matters

The oversubscribed book indicates strong investor appetite, suggesting a successful debut and potential upside for early participants.

02

Market read

First major IPO of the quarter, could set pricing tone for upcoming tech listings.

03

What to watch

possible regulatory scrutiny of wearable data privacy

Relevance 8/10Novelty 8/10Timing: pricing on Sept 29

Background

Oura, maker of health‑tracking rings, filed an S‑1 for a 50 M‑share IPO at $40‑$44 per share.

Market effects

potential boost to health‑tech IPO pipeline

adds to Nordic market activity

adds supply to Nasdaq listings

Counterpoint

if demand wanes, pricing could be trimmed, hurting early investors

Key entities

  • Oura

    Health‑fitness wearable maker planning IPO

  • Goldman Sachs

    Lead bookrunner for the offering

Related articles

$OURAHighAI 8/10

Nelson Advisors: Eli Lilly’s Strategic Stake in Oura and the Convergence of GLP-1 Therapeutics, Continuous Biometric Monitoring

Eli Lilly plans to invest up to $100M in Oura's IPO, joining Dragoneer's $300M commitment. Oura, a digital health platform, aims to raise up to $2.2B via Nasdaq listing. The company reported $1.42B revenue, $60.8M net income for the trailing year. Eli Lilly sees Oura as a strategic partner for GLP-1 therapeutic monitoring and patient retention.

$OURAHighAI 8/10

Oura’s IPO Puts AI-Powered Healthcare on the Ticker

Oura, an AI-powered healthcare company, reported 74% revenue growth to $1.21 billion in nine months. Membership revenue rose 121% to $240.5 million. Eli Lilly may invest $100 million. Oura's IPO targets a $15.62 billion valuation and will trade on Nasdaq under OURA.

$OURAHighAI 9/10

US IPO Week Ahead: Smart ring maker Oura and AI power play Accelevation headline a $2.8 billion week

Oura (OURA) plans a $2.1 billion IPO at a $15.0 billion market cap, with 73% of shares sold by existing shareholders. Accelevation (ACCV) aims to raise $660 million at a $4.9 billion valuation. Oura sells smart rings for health tracking, while Accelevation provides AI and data center infrastructure. Both IPOs are set for a $2.8 billion week.

$OURAHighAI 8/10

Oura IPO said to draw four times demand as orders near close

Oura Inc.'s IPO has drawn strong interest, with orders reaching four times the shares available, aiming to raise up to $2.2B. The company and shareholders are offering 50M shares priced between $40-$44 each. At the top of the range, Oura's market value could reach $14.1B. The IPO is set to price on Sept. 29 and trade on Nasdaq under ticker OURA.

$OURAHighAI 8/10

Oura Targets Up to $15.6 Billion Valuation in IPO, Surpassing Prada and Lululemon

Oura, a health-tracking smart ring company, aims for a $15.6 billion valuation in its U.S. IPO, selling 50 million shares at $40-$44 each, potentially raising $2.2 billion. The offering is set to price Sept. 29, with shares trading on Nasdaq under OURA. Oura reported $1.21 billion in revenue for the nine months ended June 30, up 74% year over year, with 5 million paid members.